

Accepted Manuscript

Title: Anti-angiogenic-specific adverse events in patients with non-small cell lung cancer treated with nintedanib and docetaxel

Author: Martin Reck Anders Mellemgaard Joachim von Pawel Maya Gottfried Igor Bondarenko Ying Cheng Kostas Zarogoulidis Alexander Luft Jaafar Bennouna José Barrueco Hesham Aboshady Julia Hocke Rolf Kaiser Jean-Yves Douillard<ce:collaboration id="colb0005"></ce:collaboration>



PII: S0169-5002(15)30027-1
DOI: <http://dx.doi.org/doi:10.1016/j.lungcan.2015.08.003>
Reference: LUNG 4910

To appear in: *Lung Cancer*

Received date: 11-6-2015
Revised date: 4-8-2015
Accepted date: 8-8-2015

Please cite this article as: Reck M, Mellemgaard A, von Pawel J, Gottfried M, Bondarenko I, Cheng Y, Zarogoulidis K, Luft A, Bennouna J, Barrueco J, Aboshady H, Hocke J, Kaiser R, Douillard J-Y, for the LUME-Lung 1 Study Group, Anti-angiogenic-specific adverse events in patients with non-small cell lung cancer treated with nintedanib and docetaxel, *Lung Cancer* (2015), <http://dx.doi.org/10.1016/j.lungcan.2015.08.003>

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

Highlights

- The combination of nintedanib/docetaxel was evaluated in LUME-Lung 1
- Adverse events (AEs) seen with existing anti-angiogenic agents were evaluated
- AEs associated with other agents were less pronounced with nintedanib+docetaxel

Download English Version:

<https://daneshyari.com/en/article/10910819>

Download Persian Version:

<https://daneshyari.com/article/10910819>

[Daneshyari.com](https://daneshyari.com)